Lupin Ltd
NSE:LUPIN

Watchlist Manager
Lupin Ltd Logo
Lupin Ltd
NSE:LUPIN
Watchlist
Price: 2 071.35 INR 1.39% Market Closed
Market Cap: 944.3B INR
Have any thoughts about
Lupin Ltd?
Write Note

Operating Margin
Lupin Ltd

14.5%
Current
9%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
14.5%
=
Operating Profit
30.2B
/
Revenue
208B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IN
Lupin Ltd
NSE:LUPIN
943.9B INR
15%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
710.5B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
373.5B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.1B USD
34%
CH
Roche Holding AG
SIX:ROG
202.7B CHF
32%
CH
Novartis AG
SIX:NOVN
183.3B CHF
31%
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP
21%
IE
Endo International PLC
LSE:0Y5F
146B USD
11%
Country IN
Market Cap 943.9B INR
Operating Margin
15%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 710.5B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 373.5B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 202.7B CHF
Operating Margin
32%
Country CH
Market Cap 183.3B CHF
Operating Margin
31%
Country UK
Market Cap 162.4B GBP
Operating Margin
21%
Country IE
Market Cap 146B USD
Operating Margin
11%
No Stocks Found

Lupin Ltd
Glance View

Market Cap
943.9B INR
Industry
Pharmaceuticals

Lupin Ltd. is a global pharmaceutical powerhouse rooted in Mumbai, India, renowned for its commitment to providing high-quality, affordable medicines across a spectrum of therapeutic areas. Founded in 1968, this rapidly growing company has carved a niche in generics, specialty pharmaceuticals, and biotechnology. With a robust portfolio that includes over 1,500 products across various disciplines, particularly in cardiovascular, CNS, and anti-infective medications, Lupin has established itself as a key player in the global healthcare ecosystem. The company's strategic focus on research and development ensures a steady pipeline of innovative solutions tailored to meet the needs of patients and healthcare providers alike, positioning Lupin as a dynamic leader in the pharmaceutical industry. Driven by a global vision, Lupin operates in over 100 countries and has earned a reputation for excellence through its extensive manufacturing capabilities and adherence to stringent quality standards. The firm’s dedication to expanding its presence in developed markets, particularly in the U.S. and Europe, underscores its ambition to enhance healthcare access worldwide. For investors, Lupin represents an opportunity characterized by solid growth potential, as it continuously invests in R&D, strengthens its market position, and adapts to the evolving landscape of global healthcare. With a commitment to sustainability and a focus on creating value for stakeholders, Lupin Ltd. not only aims to thrive financially but also to enrich the lives of millions through its innovative healthcare solutions.

LUPIN Intrinsic Value
1 418.64 INR
Overvaluation 32%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
14.5%
=
Operating Profit
30.2B
/
Revenue
208B
What is the Operating Margin of Lupin Ltd?

Based on Lupin Ltd's most recent financial statements, the company has Operating Margin of 14.5%.